

METHODS FOR TREATING DISEASES CAUSED BY DEFICIENCIES OF
RECOMBINANT α -L-IDURONIDASE

ABSTRACT

5 The present invention provides a formulation comprising a pharmaceutical
composition comprising a human recombinant α -L-iduronidase or biologically active or
muted thereof with a purity of greater than 99%, or in combination with a
pharmaceutically acceptable carrier. The present invention further provides methods to
treat certain genetic disorders including α -L-iduronidase deficiency and
10 mucopolysaccharidosis I (MPS 1) by administering said formulation.